Atropine
- Generic Name
- Atropine
- Brand Names
- Atnaa, Atropen, Busulfex, Donnatal, Duodote, Enlon-plus, Isopto Atropine, Lomotil, Minims Atropine Sulphate, Motofen, Phenohytro
- Drug Type
- Small Molecule
- Chemical Formula
- C17H23NO3
- CAS Number
- 51-55-8
- Unique Ingredient Identifier
- 7C0697DR9I
- Background
Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active. Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosseous, endotracheal and ophthalmic methods. Oral atropine ...
- Indication
The intravenous, intramuscular, subcutaneous, intraosseous and endotracheal use of atropine is indicated for the temporary blockade of severe or life-threatening muscarinic effects. The intramuscular use of atropine in the form of a pen injector is indicated for the treatment of poisoning by susceptible organophosphorus nerve agents having cholinesterase act...
- Associated Conditions
- Amblyopia, Atrioventricular Heart-block, Bradycardia, Bronchospasm, Crying, Detrusor Hyperreflexia, Excessive bronchial secretion, Hypertonic uterine contraction, Hypertonicity of the small intestine, Ocular Inflammation, Parkinsonism, Peptic Ulcer, Poisoning by parasympathomimetics (cholinergics), Poisoning caused by mushrooms, Poisoning caused by organophosphate anticholinesterase nerve agents, Poisoning caused by organophosphorus pesticides, Pylorospasm, Rhinorrhoea, Sinus Bradycardia, Spasms, Toxic effect of organophosphate and carbamate, Hypermobility of the colon, Laughing, Life-threatening muscarinic side effects, Muscarinic side effects, Severe muscarinic side effects
- Associated Therapies
- -
Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma Therapy
- First Posted Date
- 2007-12-18
- Last Posted Date
- 2008-01-25
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 31
- Registration Number
- NCT00575523
- Locations
- 🇦🇹
Div. of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
Study of Myopia Prevention in Children With Low Concentration of Atropine
- First Posted Date
- 2007-10-10
- Last Posted Date
- 2007-10-10
- Lead Sponsor
- Min-Sheng General Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT00541177
- Locations
- 🇨🇳
Min-Sheng General Hospital, Tao-Yuan, Taiwan
Combined Patching-Atropine for Residual Amblyopia
- First Posted Date
- 2007-07-25
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- Jaeb Center for Health Research
- Target Recruit Count
- 55
- Registration Number
- NCT00506675
- Locations
- 🇺🇸
Duke University Eye Center, Durham, North Carolina, United States
Effects of Exendin(9-39) on Gastroduodenal Motility
- Conditions
- Interventions
- First Posted Date
- 2007-05-01
- Last Posted Date
- 2015-04-01
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Target Recruit Count
- 10
- Registration Number
- NCT00468091
- Locations
- 🇩🇪
Clinical Research unit, Dept. of Internal Medicine II - Großhadern, University of Munich, Munich, Germany
Mechanisms of Choroidal Blood Flow Changes During Dark/Light Transitions
- Conditions
- First Posted Date
- 2007-02-05
- Last Posted Date
- 2007-02-05
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 42
- Registration Number
- NCT00431392
- Locations
- 🇦🇹
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
Trial Comparing Atropine to Atropine Plus a Plano Lens for the Sound Eye for Amblyopia in Children 3 to <7 Years Old
- First Posted Date
- 2006-04-18
- Last Posted Date
- 2016-07-19
- Lead Sponsor
- Jaeb Center for Health Research
- Target Recruit Count
- 240
- Registration Number
- NCT00315302
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Southern California College of Optometry, Fullerton, California, United States
Trial Comparing Patching Versus Atropine for Amblyopia in 7 to < 13 Year Olds
- Conditions
- Interventions
- First Posted Date
- 2006-04-18
- Last Posted Date
- 2016-06-24
- Lead Sponsor
- Jaeb Center for Health Research
- Target Recruit Count
- 233
- Registration Number
- NCT00315328
- Locations
- 🇺🇸
Pennsylvania College of Optometry, Philadelphia, Pennsylvania, United States
🇺🇸Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation
- Conditions
- First Posted Date
- 2006-01-26
- Last Posted Date
- 2014-05-12
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 31
- Registration Number
- NCT00282282
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Analysis of Atropine and Propranolol Induced Changes
- First Posted Date
- 2005-11-10
- Last Posted Date
- 2012-08-06
- Lead Sponsor
- National Institute on Aging (NIA)
- Target Recruit Count
- 24
- Registration Number
- NCT00251602
- Locations
- 🇺🇸
National Institute on Aging, Harbor Hospital, Baltimore, Maryland, United States
Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-07-30
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT00153985
- Locations
- 🇺🇸
Winship Cancer Institute-Emory University, Atlanta, Georgia, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.